CROI 2022: No impact from high-dose vitamin D3 on reducing the HIV viral reservoir
Simon Collins, HIV i-Base
This pilot study randomised 30 people on effective ART to either high-dose oral vitamin D3 (10,000 international units daily) for 24 weeks or a matching placebo.
There were no differences in the primary endpoint of changes in HIV DNA in cells over the 24 weeks (p=0.19) – a marker for waking cells in the reservoir,
However, there was a 1.24 (95% CIL 1.01 to 1.51) fold increase (p = 0.039) from week 0 to week 12 and a 0.76 (95% CI: 0.62 to 0.94) fold decrease (p = 0.009) from week 0 to week 36 in frequency of total HIV DNA relative to placebo.
Vitamin D3 levels remained high at week 36 due to long half-life but there were no safety issues from the study.
Pitman MC et al. Effect of high-dose vitamin D3 on the HIV reservoir: a randomised controlled trial. CROI 2022, 12–16 and 22–24 February, virtual meeting. Poster abstract 355.
This report was first published on 15 February 2022.